TargetBeta
TNFSF13
TNF superfamily member 13 · also APRIL, CD256 · CD molecules
2 programs in company-led studies act on TNFSF13, from 2 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| sibeprenlimabrule | Otsuka | phase 3 | 86 running | – | ChEMBL |
| zigakibart | Novartis | phase 3 | 63 running | – | the company's pipeline |
Conditions their studies are in
- Glomerulonephritis, IGA, 2 programs
- Autoimmune Diseases, 1 program
- Multiple Myeloma, 1 program
- Nephrosis, Lipoid, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 13, 2027sibeprenlimab · Otsuka · phase 3 · NCT06928142
- Aug 10, 2027zigakibart · Novartis · phase 3 · NCT05852938
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.